What’s new: Chinese graft busters are investigating Zhou Bin, former deputy general manager of state-owned drugmaker China National Pharmaceutical Group Co. Ltd. (Sinopharm), as Beijing continues its crackdown on health care corruption launched last year.
Zhou is suspected of “serious violations of (Communist Party) discipline and law,” a common euphemism for corruption, according to a brief statement published Wednesday by the Central Commission for Discipline Inspection, the party’s top graft watchdog.
